administr
influenza
vaccin
via
respiratori
tract
potenti
benefit
convent
parenter
administr
induc
immun
directli
site
influenza
exposur
well
needl
free
studi
investig
suitabl
stabl
particul
polymorph
inulin
also
refer
delta
inulin
mucos
adjuv
whole
inactiv
influenza
vaccin
wiv
administ
either
liquid
dri
powder
formul
spray
freezedri
produc
advaxadjuv
wiv
powder
particl
size
rang
suitabl
inhal
physic
biolog
characterist
wiv
advax
remain
unalt
admix
wiv
advax
spray
freez
dri
upon
intranas
pulmonari
immun
liquid
dri
powder
formul
contain
advax
induc
significantli
higher
system
mucos
cellular
immun
respons
nonadjuv
wiv
formul
furthermor
pulmonari
immun
advaxadjuv
wiv
led
robust
memori
b
cell
respons
along
increas
lung
local
factor
ie
less
pronounc
still
posit
effect
advax
seen
memori
cell
respons
contrast
anim
immun
wiv
alon
anim
pulmonari
immun
singl
dose
advaxadjuv
wiv
fulli
protect
visibl
clinic
symptom
lethal
dose
influenza
viru
data
confirm
advax
potent
mucos
adjuv
boost
vaccineinduc
humor
cellular
immun
respons
lung
system
major
posit
effect
bcell
memori
complet
protect
live
viru
henc
respiratori
tract
immun
particularli
via
lung
advaxadjuv
wiv
formul
liquid
dri
powder
promis
altern
parenter
influenza
vaccin
influenza
highli
contagi
diseas
affect
million
peopl
worldwid
annual
basi
season
epidem
sporad
pandem
influenza
caus
transmiss
influenza
viru
via
aerosol
sinc
respiratori
tract
portal
influenza
viru
entri
intheori
best
mean
protect
would
use
vaccin
gener
local
memori
immun
respons
abl
neutral
viru
site
infect
howev
major
current
avail
influenza
vaccin
administ
via
intramuscular
subcutan
inject
inject
vaccin
gener
strong
system
immun
minim
mucos
immun
moreov
inject
vaccin
caus
local
reaction
includ
pain
swell
red
inject
site
needl
phobia
transmiss
infecti
diseas
due
needl
stick
injuri
influenza
vaccin
formul
could
administ
via
respiratori
tract
would
overcom
drawback
current
inject
formul
therefor
need
due
live
natur
viru
approv
use
high
risk
group
problem
could
avoid
use
inactiv
influenza
vaccin
formul
suitabl
deliveri
via
respiratori
tract
alreadi
waldman
et
al
report
pulmonari
vaccin
administr
effect
convent
im
administr
prevent
influenza
associ
ill
pulmonari
vaccin
deliv
liquid
dri
powder
preclin
studi
pulmonari
deliveri
liquid
dri
powder
influenza
vaccin
formul
shown
induc
mucos
well
system
immun
respons
howev
magnitud
immun
respons
evok
nonadjuv
vaccin
low
low
mucos
iga
titer
low
number
memori
cell
might
result
short
live
protect
infect
issu
might
solv
use
suitabl
adjuv
boost
immun
memori
respons
abl
elicit
respiratori
tract
administr
influenza
vaccin
identif
adjuv
suitabl
administr
via
respiratori
tract
easi
parenter
administr
adjuv
current
approv
intranas
pulmonari
use
clinic
problem
develop
mucos
adjuv
influenza
vaccin
highlight
issu
rare
case
facial
palsi
clinic
trial
subject
administ
intranas
inactiv
influenza
vaccin
contain
latent
toxin
adjuv
result
vaccin
abandon
current
approv
altern
alum
effect
influenza
vaccin
addit
caus
inflammasom
activ
local
cell
necrosi
dna
releas
form
insolubl
aggreg
render
unsuit
pulmonari
use
current
approv
influenza
vaccin
adjuv
base
squalen
oil
emuls
restrict
subcutan
intramuscular
use
moreov
administr
oilbas
emuls
respiratori
tract
like
detriment
normal
balanc
alveolar
line
fluid
thu
interf
lung
function
newer
experiment
adjuv
tolllik
receptor
agonist
work
via
activ
howev
key
induc
inflammatori
respons
therefor
pulmonari
administr
agonist
may
induc
unaccept
lung
inflamm
henc
number
candid
adjuv
like
suitabl
respiratori
tract
use
limit
adjuv
shown
good
safeti
toler
record
upon
parenter
administr
inactiv
recombin
influenza
vaccin
anim
model
clinic
trial
advax
advax
adjuv
compos
insolubl
particul
polymorph
inulin
also
refer
delta
inulin
inulin
make
advax
adjuv
rapidli
excret
bodi
renal
excret
complet
clearanc
within
approxim
week
parenter
administr
advax
adjuv
compris
discoid
shape
particl
diamet
form
assembl
seri
lamellar
crystallin
sheet
adjuvant
parenter
administ
vaccin
advax
shown
improv
immunogen
protect
capac
sever
vaccin
candid
hepat
b
anthrax
sever
acut
respiratori
syndrom
sar
coronaviru
listeria
influenza
exact
mechan
advax
boost
immun
respons
upon
parenter
administr
still
investig
till
date
howev
use
advax
adjuv
vaccin
deliv
via
respiratori
tract
less
well
investig
singl
studi
murugappan
et
al
show
pulmonari
coadministr
liquid
influenza
vaccin
formul
advax
induc
balanc
profil
modest
increas
nasal
iga
titer
enhanc
humor
cellular
immun
respons
found
use
advax
dose
also
potenti
advax
boost
immun
respons
altern
commonli
use
mucos
rout
intranas
incorpor
altern
physic
form
powder
investig
studi
present
studi
investig
whether
advax
adjuv
could
augment
immun
respons
whole
inactiv
influenza
vaccin
wiv
administ
respiratori
tract
via
intranas
pulmonari
rout
either
dri
powder
liquid
formul
investig
mechan
wherebi
advax
enhanc
immun
respons
influenza
vaccin
administ
via
respiratori
tract
lastli
explor
whether
singl
pulmonari
immun
low
dose
wiv
adjuv
advax
would
provid
protect
lethal
viral
challeng
immun
studi
influenza
strain
nibrg
reassort
viru
grown
embryon
chicken
egg
allanto
inocul
seed
viru
purifi
describ
previous
challeng
experi
mouseadapt
influenza
viru
propag
allanto
fluid
old
embryon
hen
egg
use
live
viru
inactiv
overnight
treatment
acro
organ
geel
belgium
citrat
buffer
mm
sodium
citrat
mm
sodium
chlorid
ph
inactiv
viru
dialyz
overnight
hepe
buffer
mm
nacl
mm
hepe
ph
steril
autoclav
complet
remov
protein
content
wiv
prepar
determin
microlowri
assay
hemagglutinin
ha
assum
total
protein
content
inactiv
viru
sprayfreez
dri
sfd
perform
mix
wiv
wivadvax
adjuv
vaxin
pti
ltd
adelaid
australia
ha
advax
ww
water
solubl
form
inulin
use
lyoprotect
bulk
agent
kda
sensu
roosenda
netherland
wiv
wivadvax
formul
ha
inulin
weight
ratio
respect
thu
obtain
dispers
composit
ha
inulin
ww
ha
advax
inulin
www
ha
inulin
weight
ratio
base
upon
dose
ha
without
advax
mg
sfd
powder
twofluid
nozzl
diamet
mm
buchi
mini
spray
dryer
buchi
flawil
switzerland
use
pump
dispers
flow
rate
mlmin
spray
vessel
liquid
nitrogen
use
atom
airflow
l
n
h
dri
perform
christ
epsilon
freez
dryer
shelf
temperatur
pressur
mbar
shelf
temperatur
gradual
increas
time
period
h
secondari
dri
temperatur
gradual
increas
pressur
lower
mbar
consecut
h
vaccin
powder
collect
climat
box
rel
humid
store
airtight
condit
size
wiv
addit
advax
determin
dynam
light
scatter
dl
malvern
zetas
malvern
unit
kingdom
likewis
size
advax
also
measur
addit
wiv
sampl
prepar
wiv
advax
either
use
alon
mix
ha
advax
ratio
ww
particl
size
analysi
done
use
zetas
softwar
transmiss
electron
microscopi
tem
imag
captur
use
philip
transmiss
electron
microscop
sfd
powder
contain
advax
reconstitut
steril
filter
water
liquid
reconstitut
sfd
advax
contain
formul
place
plain
carbon
grid
rins
water
sampl
stain
twice
wt
uranyl
acet
imag
taken
gatan
type
ultrascan
ccd
camera
magnif
morpholog
sfd
powder
analyz
scan
electron
microscopi
sem
use
jeol
jsm
microscop
doubl
side
sticki
carbon
tape
metal
disc
use
powder
place
particl
coat
nm
gold
use
balzer
sputter
devic
balzer
union
austria
imag
captur
magnif
primari
particl
size
distribut
sfd
powder
determin
laser
diffract
powder
dispers
pressur
bar
rodo
sympatec
clausthalzellerfeld
germani
use
dispers
nm
len
use
fraunhof
theori
use
calcul
geometr
particl
size
distribut
receptor
bind
activ
wiv
sfd
assess
hemagglutin
assay
describ
previous
briefli
wiv
reconstitut
pb
ad
v
bottom
plate
contain
pb
twofold
serial
dilut
prepar
guinea
pig
red
blood
cell
suspens
ad
well
plate
incub
h
room
temperatur
hemagglutin
titer
read
h
hemagglutin
titer
express
log
highest
dilut
rbc
agglutin
could
seen
groningen
netherland
permit
number
flinder
univers
adelaid
australia
permit
number
invivo
experi
carri
week
old
femal
balbc
mice
elevag
janvier
le
genetsstisl
franc
mice
randomli
divid
eight
group
consist
micegroup
order
investig
whether
coadministr
advax
influenza
vaccin
would
boost
immun
respons
weakli
immunogen
strain
influenza
viru
chosen
mice
immun
wiv
howev
routin
influenza
vaccin
field
given
ha
domin
protect
antigen
dose
use
immun
repres
ha
content
total
protein
content
inactiv
viru
mice
vaccin
twice
week
interv
vaccin
formul
contain
ha
intramuscular
im
vaccin
vaccin
formul
contain
ha
without
adjuv
divid
hind
leg
intranas
immun
vaccin
formul
contain
ha
without
advax
ha
advax
slowli
administ
use
pipett
nare
nare
pulmonari
administr
liquid
vaccin
pul
liq
vaccin
contain
ha
without
advax
ha
advax
administ
trachea
mice
via
microsyring
follow
insuffl
air
assur
deep
lung
deposit
vaccin
powder
deliveri
pul
pow
mg
powder
contain
ha
without
advax
ha
advax
administ
lung
anim
appli
three
puff
air
via
dri
powder
insuffl
describ
previous
neg
control
anim
left
untreat
day
second
immun
blood
collect
retroorbit
punctur
one
week
second
vaccin
dose
mice
sacrif
obtain
sera
store
analysi
nose
wash
bronchioalveolar
lavag
bal
collect
flush
ml
pb
contain
complet
proteas
inhibitor
cocktail
tablet
roch
almer
netherland
nasopharynx
lung
respect
lavag
store
use
spleen
lung
collect
complet
imdm
media
contain
uml
penicillin
mgml
streptomycin
invitrogen
breda
netherland
fetal
calf
serum
lonza
basel
switzerland
spleen
process
singl
cell
suspens
pass
cell
strainer
follow
rbc
lysi
use
hypoton
medium
nh
cl
mm
khco
mm
edta
ph
bone
marrow
treat
similar
way
spleen
process
singl
cell
suspens
lung
process
singl
cell
suspens
describ
previous
splenocyt
bone
marrow
cell
use
individu
mice
lung
lymphocyt
pool
per
experiment
group
lung
lymphocyt
pool
experiment
group
due
lack
enough
cell
individu
anim
number
readout
investig
studi
sera
nose
wash
bal
use
determin
influenzaspecif
antibodi
respons
igg
iga
antibodi
detect
overnight
coat
elisa
plate
grenier
bioon
alphen
netherland
ngwell
wiv
elisa
perform
describ
previous
absorb
measur
nm
use
synergi
ht
reader
biotek
winooski
usa
determin
averag
igg
titer
log
reciproc
sampl
dilut
correspond
absorb
nm
use
nose
lung
iga
level
present
averag
absorb
nm
undilut
nose
lung
wash
hemagglutin
inhibit
hi
assay
perform
describ
previous
briefli
sera
pool
experiment
group
hemagglutin
unit
hau
inactiv
viru
ad
twofold
dilut
serum
sampl
sera
pool
sampl
volum
individu
anim
enough
assay
hi
titer
record
highest
serum
dilut
capabl
prevent
hemagglutin
rbc
microneutr
assay
mn
perform
describ
previous
briefli
well
viru
ad
twofold
serial
dilut
sera
sampl
incub
h
h
virusserum
mixtur
transfer
mdck
cell
incub
h
thereaft
virusserum
mixtur
discard
cultur
supernat
supplement
medium
contain
tpck
trypsin
incub
addit
h
subsequ
mn
titer
calcul
record
hemagglutin
activ
highest
serum
dilut
capabl
prevent
hemagglutin
b
cell
elispot
perform
previous
describ
modif
multiscreenhtsha
filter
plate
millipor
billerica
massachusett
coat
overnight
cell
wash
three
time
pb
contain
tween
twice
pb
plate
block
bsa
h
lymphocyt
lung
splenocyt
imdm
complet
medium
fb
ad
well
incub
h
co
follow
incub
cell
wash
pb
contain
tween
subsequ
alkalin
phosphatas
label
antimous
iga
antibodi
sigmaaldrich
chemi
bv
zwijndrecht
netherland
hors
radish
peroxidas
label
antimous
igg
antibodi
southernbiotech
birmingham
usa
ad
well
incub
h
well
wash
thoroughli
pb
contain
tween
number
iga
igg
antibodi
secret
cell
asc
identifi
use
phosphat
bcip
nitro
blue
tetrazolium
nbt
aec
substrat
roch
almer
netherland
respect
spot
count
use
elispot
reader
aelvi
elispot
reader
hannov
germani
number
produc
cell
spleen
determin
use
readi
setgo
elispot
kit
ebiosci
vienna
austria
briefli
splenocyt
lymphocyt
lung
ad
multiscreenhtsha
filter
plate
precoat
antibodi
plate
incub
overnight
co
imdm
complet
medium
without
wiv
elispot
plate
stain
per
manufactur
protocol
spot
count
use
elvi
elispot
reader
determin
level
spleen
immun
mice
readi
setgo
elisa
kit
r
system
biotechn
minnesota
usa
use
accord
manufactur
protocol
briefli
splenocyt
lymphocyt
lung
ad
round
bottom
plate
incub
overnight
co
imdm
complet
medium
without
wiv
cell
supernat
collect
store
use
challeng
studi
femal
balbc
mice
week
age
n
immun
via
pulmonari
rout
wiv
without
mg
advax
adjuv
rational
wiv
immun
dose
challeng
studi
found
optim
vaccin
dose
see
differ
group
clinic
outcom
wherea
ha
found
optim
dose
see
differ
group
immunogen
measur
hi
mn
vaccin
administ
anaesthesia
use
intratrach
intub
microspray
two
week
immun
anim
challeng
live
viru
mous
lethal
dose
ld
viru
estim
adult
balbc
mice
reedmuench
method
one
ld
correspond
tcid
mdck
cell
data
shown
viru
challeng
dose
use
tcid
administ
intranas
volum
gave
lethal
control
nonimmun
mice
daili
weight
sick
score
system
base
coat
condit
postur
activ
use
assess
extent
clinic
diseas
mice
evalu
daili
ruffl
fur
absent
slightli
present
present
hunch
back
absent
slightli
present
present
activ
normal
reduc
sever
reduc
final
score
addit
individu
symptom
score
eg
anim
show
slightli
ruffl
fur
slightli
hunch
back
reduc
activ
score
mice
euthan
develop
clinic
score
mann
whitney
u
test
perform
statist
analysi
data
two
tail
test
perform
compar
nonadjuv
vs
adjuv
im
vs
adjuv
wiv
formul
p
valu
consid
signific
repres
p
valu
less
equal
respect
coxmantel
log
rang
test
use
compar
differ
surviv
advaxadjuv
wiv
group
wiv
alon
ie
without
adjuv
use
advax
mucos
adjuv
wiv
essenti
detriment
effect
physic
biolog
properti
inactiv
viru
particl
sfd
impact
physic
characterist
advax
dl
measur
reveal
mix
advax
neglig
effect
size
wiv
liquid
wiv
without
adjuv
size
nm
advaxadjuv
liquid
wiv
formul
size
nm
fig
likewis
size
advax
particl
remain
unalt
advax
nm
advaxadjuv
wiv
formul
nm
furthermor
evalu
whether
sfd
impact
physic
appear
advax
particl
advax
sfd
without
wiv
presenc
water
solubl
inulin
stabil
tem
analysi
reveal
advax
particl
compar
morpholog
sfd
fig
order
investig
whether
advax
effect
physic
characterist
sfd
powder
formul
physic
appear
powder
particl
analyz
sem
sem
imag
reveal
intact
spheric
shape
particl
interconnect
porou
structur
sfd
wiv
without
adjuv
fig
sfd
advaxadjuv
wiv
formul
fig
upon
dispers
rodo
averag
geometr
particl
size
x
sfd
advaxadjuv
wiv
formul
found
compar
sfd
nonadjuv
wiv
formul
ie
respect
fig
import
criterion
particl
suitabl
inhal
aerodynam
particl
size
ideal
aerodynam
particl
size
calcul
accord
formula
describ
bhide
et
al
aerodynam
particl
size
wiv
advaxadjuv
wiv
sfd
found
requir
size
rang
ie
thu
indic
suitabl
formul
pulmonari
immun
fig
thu
upon
sfd
wiv
formul
either
without
advax
powder
particl
similar
size
morpholog
form
make
fair
comparison
nonadjuv
advaxadjuv
sfd
powder
possibl
well
known
exist
ha
nativ
conform
crucial
receptor
bind
activ
induct
immun
respons
thu
order
evalu
whether
receptor
bind
activ
ha
preserv
addit
advax
sfd
hemagglutin
assay
perform
formul
show
similar
hemagglutin
titer
indic
admix
wiv
advax
sfd
destabil
effect
ha
fig
overal
data
show
sfd
use
produc
advaxadjuv
wiv
dri
powder
formul
suitabl
pulmonari
administr
previou
preclin
clinic
studi
shown
coadministr
influenza
vaccin
advax
via
convent
parenter
rout
substanti
enhanc
system
immun
thu
order
investig
potenti
advax
mucos
adjuv
system
immun
respons
determin
either
three
week
first
day
one
week
second
immun
day
time
point
nonvaccin
anim
use
neg
control
found
previou
studi
immun
advax
alon
detect
effect
immun
paramet
compar
mice
inject
salin
unpublish
data
moreov
influenza
specif
immun
respons
measur
therefor
paramet
might
induc
use
advax
alon
could
quantifi
henc
advax
alon
group
includ
studi
first
evalu
number
igg
iga
asc
splenocyt
mice
vaccin
nonadjuv
advaxadjuv
wiv
formul
fig
found
respiratori
tract
immun
advaxadjuv
wiv
formul
either
liquid
powder
led
left
right
side
sem
pictur
captur
magnif
respect
e
geometr
particl
size
sfd
wiv
advaxadjuv
wiv
dispers
rodo
n
f
aerodynam
particl
size
sfd
wiv
advaxadjuv
wiv
g
hemagglutin
titer
wiv
advaxadjuv
wiv
sfd
n
differ
found
among
triplic
within
group
data
present
averag
standard
error
mean
fig
e
f
significantli
higher
number
igg
iga
asc
immun
correspond
nonadjuv
wiv
formul
expect
deliveri
wiv
via
im
rout
led
product
iga
asc
consider
number
igg
asc
spleen
fig
next
evalu
serum
antiinfluenza
igg
titer
first
second
immun
im
respiratori
tract
deliveri
wiv
formul
without
advax
induc
serum
igg
respons
first
immun
increas
booster
dose
fig
furthermor
respiratori
tract
deliveri
advaxadjuv
wiv
formul
either
liquid
powder
gener
significantli
higher
igg
titer
correspond
nonadjuv
wiv
formul
second
immun
higher
serum
igg
titer
induc
advaxadjuv
wiv
formul
line
signific
increas
splenic
igg
asc
serum
igg
titer
gener
respiratori
tract
administ
advaxadjuv
wiv
formul
compar
gener
nonadjuv
wiv
formul
given
via
im
rout
day
day
fig
coher
igg
titer
respons
significantli
enhanc
mice
immun
advaxadjuv
wiv
formul
via
respiratori
tract
versu
mice
immun
nonadjuv
wiv
formul
fig
howev
respons
significantli
enhanc
advaxadjuv
wiv
formul
liquid
powder
administ
lung
administr
fig
moreov
balanc
ratio
observ
indic
advaxadjuv
wiv
induc
balanc
type
immun
respons
agreement
previou
studi
balanc
ratio
observ
pulmonari
administr
liquid
advaxadjuv
wiv
formul
function
potenti
igg
antibodi
serum
assess
hi
mn
assay
day
day
advaxadjuv
wiv
formul
administ
lung
induc
substanti
higher
hi
titer
nonadjuv
wiv
formul
fig
line
hi
titer
approxim
fivesix
fold
higher
mn
titer
seen
advaxadjuv
wiv
formul
administ
respiratori
tract
correspond
nonadjuv
wiv
formul
fig
higher
hi
mn
titer
advaxadjuv
wiv
consist
higher
serum
igg
titer
thu
indic
function
effect
vaccineinduc
igg
antibodi
group
thu
advaxadjuv
wiv
formul
administ
respiratori
tract
induc
compar
system
immun
respons
wiv
administ
via
im
rout
consider
higher
immun
respons
nonadjuv
respiratori
tract
administ
wiv
import
goal
influenza
vaccin
induct
antibodi
respiratori
tract
portal
influenza
viru
entri
tradit
parenter
rout
influenza
vaccin
administr
ineffici
induc
mucos
immun
respons
similarli
pulmonari
immun
nonadjuv
wiv
gener
induc
low
level
local
mucos
immun
order
investig
potenti
advax
boost
local
mucos
immun
respiratori
tract
immun
determin
week
second
immun
assess
nasal
iga
bal
antiinfluenza
iga
igg
level
along
asc
lung
expect
wiv
administ
via
im
rout
fail
induc
substanti
nasal
lung
iga
titer
fig
b
compar
im
rout
higher
nose
iga
titer
found
advaxadjuv
wiv
formul
administ
respiratori
tract
howev
significantli
higher
liquid
formul
administ
nose
powder
formul
administ
lung
fig
yet
compar
nonadjuv
wiv
formul
advaxadjuv
liquid
formul
administ
lung
elicit
significantli
higher
nasal
iga
titer
contrast
signific
effect
advax
adjuv
seen
bal
iga
pulmonari
vaccin
group
approxim
foureightfold
higher
lung
iga
titer
mice
immun
correspond
nonadjuv
wiv
formul
fig
henc
advax
either
administ
lung
increas
lung
nasal
iga
product
might
due
rel
smaller
surfac
area
nasal
mucosa
compar
lower
respiratori
tract
sinc
ml
pb
use
collect
nasal
lung
wash
concentr
iga
lung
wash
would
expect
much
higher
nasal
wash
amount
iga
per
specif
surfac
area
lung
nose
would
fact
pulmonari
powder
liquid
deliveri
adjuv
wiv
alon
induc
increas
nasal
iga
might
suggest
powder
particl
may
exhal
mice
back
bronchi
nasal
nare
insuffl
procedur
wherea
liquid
vaccin
may
like
instantli
adher
bronchial
wall
therebi
remain
suspend
air
abl
escap
nose
advaxadjuv
wiv
formul
administ
respiratori
tract
significantli
increas
antiinfluenza
igg
titer
lung
accord
increas
serum
igg
titer
seen
anim
compar
correspond
nonadjuv
wiv
immun
fig
interestingli
lung
igg
titer
mice
immun
wivadvax
formul
administ
respiratori
tract
significantli
higher
immun
nonadjuv
wiv
formul
via
im
rout
fig
boost
lung
iga
igg
titer
advaxadjuv
respiratori
tract
immun
wiv
consist
increas
number
iga
igg
asc
found
lung
mice
fig
henc
inclus
advax
wiv
formul
result
significantli
higher
mucos
humor
immun
respons
nonadjuv
wiv
formul
administ
via
respiratori
tract
via
im
rout
phenotyp
immun
respons
skew
balanc
consid
import
protect
potenti
balanc
respons
prefer
aid
viru
neutral
clearanc
order
investig
whether
incorpor
advax
wiv
formul
deliveri
adjuv
vaccin
respiratori
tract
influenc
type
magnitud
cellmedi
immun
respons
induc
frequenc
influenzaspecif
secret
splenic
cell
determin
addit
level
measur
supernat
splenocyt
stimul
invitro
wiv
compar
wiv
alon
advaxadjuv
wiv
formul
associ
signific
increas
number
secret
influenzaspecif
cell
fig
likewis
increas
product
seen
advaxadjuv
wiv
group
compar
nonadjuv
wiv
although
differ
signific
pulmonari
immun
group
fig
moreov
advaxadjuv
wiv
associ
significantli
higher
frequenc
secret
cell
well
significantli
higher
amount
cultur
supernat
compar
wiv
alon
fig
contrast
im
administ
wiv
induc
high
number
secret
cell
low
number
secret
cell
fig
c
match
level
measur
cultur
supernat
fig
thu
immun
advaxadjuv
wiv
via
respiratori
tract
led
balanc
respons
wherea
im
immun
wiv
alon
predominantli
induc
predomin
immun
respons
advaxadjuv
wiv
administ
either
liquid
powder
formul
induc
compar
humor
cellular
immun
respons
administ
via
pulmonari
rout
henc
liquid
advaxadjuv
wiv
use
repres
formul
mechanist
investig
type
b
cell
respond
immun
antigenactiv
b
cell
undergo
isotyp
class
switch
chang
product
antibodi
subtyp
igm
igd
igg
iga
ige
order
character
phenotyp
class
switch
b
cell
determin
fraction
memori
b
cell
among
total
number
class
switch
b
cell
pulmonari
deliveri
wiv
alon
advax
adjuv
previou
studi
shown
memori
b
cell
particularli
lung
play
key
role
protect
influenza
reinfect
memori
b
cell
identifi
express
henc
cell
isol
lung
spleen
bone
marrow
stain
igmigd
identifi
igmigd
class
switch
cell
memori
b
cell
marker
fig
advaxadjuv
wiv
administ
via
pulmonari
rout
led
increas
frequenc
memori
b
cell
lung
spleen
bone
marrow
comparison
administr
wiv
alon
fig
analysi
cell
reveal
lung
spleen
percentag
memori
b
cell
particularli
high
among
igg
produc
cell
fig
bone
marrow
high
among
iga
produc
b
cell
fig
contrast
much
lower
number
b
cell
seen
immun
group
although
still
fold
increas
lung
memori
b
cell
among
igg
iga
produc
cell
observ
advaxadjuv
wiv
group
compar
wiv
alon
group
fig
c
data
suggest
respiratori
tract
immun
particular
pulmonari
immun
advaxadjuv
wiv
induc
larg
number
classswitch
igg
iga
memori
b
cell
igg
memori
b
cell
primarili
traffick
lung
spleen
iga
memori
b
cell
instead
traffick
bone
marrow
previou
studi
shown
promot
lung
home
b
cell
effector
cell
infect
influenza
viru
pulmonari
immun
advaxadjuv
wiv
increas
percentag
classswitch
b
cell
express
lung
local
marker
fig
slight
increas
percentag
express
fig
interestingli
immun
advaxadjuv
wiv
induc
increas
b
cell
increas
express
b
cell
fig
f
likewis
pulmonari
immun
advaxadjuv
wiv
enhanc
number
classswitch
b
cell
express
fig
overal
respiratori
tract
deliveri
particular
pulmonari
deliveri
advaxadjuv
wiv
increas
frequenc
classswitch
memori
b
cell
enhanc
express
local
factor
ie
classswitch
b
cell
memori
cell
assum
key
player
promot
product
longliv
asc
memori
b
cell
thu
facilit
rapid
product
antibodi
case
antigen
recal
effectormemori
cell
identifi
express
absenc
thu
denot
pulmonari
immun
advaxadjuv
wiv
led
increas
lung
effectormemori
cell
comparison
administr
wiv
alon
fig
previou
studi
shown
even
absenc
b
cell
effectormemori
cell
effectormemori
cell
provid
least
partial
protect
influenza
infect
recruit
effectormemori
cell
lung
recruit
facilit
express
lung
local
factor
effectormemori
cell
tissu
resid
memori
cell
trm
subset
memori
cell
express
lack
properti
recircul
remain
restrict
within
tissu
therebi
make
readili
avail
protect
local
infect
besid
express
effectormemori
known
promot
migrat
local
infect
lung
therefor
character
effectormemori
cell
express
lung
local
factor
tissu
resid
cell
marker
immun
advaxadjuv
wiv
formul
show
minor
increas
percentag
cell
compar
correspond
nonadjuv
wiv
formul
contrast
pulmonari
administr
advaxadjuv
wiv
enhanc
percentag
effectormemori
express
fig
consist
previou
studi
also
found
augment
express
effectormemori
cell
led
increas
migrat
cell
lung
fig
stain
trm
marker
reveal
adjuvant
advax
led
approxim
increas
trm
lung
pulmonari
well
administ
vaccin
fig
thu
immun
mice
advaxadjuv
wiv
particular
via
pulmonari
rout
increas
effectormemori
cell
augment
express
cell
lung
consist
previou
studi
show
mucos
administr
antigen
necessari
gener
local
cell
respons
conclus
coadministr
wiv
advax
result
enhanc
number
effectormemori
cell
moder
increas
express
lung
local
factor
trm
cell
marker
respiratori
tract
immun
pulmonari
advaxadjuv
wiv
shown
experi
boost
humor
cellular
immun
system
local
lung
howev
mechanist
studi
mainli
pulmonari
immun
advaxadjuv
wiv
found
boost
memori
respons
express
lung
local
factor
henc
pulmonari
rout
chosen
challeng
studi
challeng
studi
explor
whether
enhanc
immun
translat
enhanc
protect
mice
expos
lethal
dose
influenza
viru
maxim
stringenc
model
mice
receiv
singl
dose
pulmonari
wiv
without
advax
advax
alon
without
antigen
control
group
includ
previou
studi
level
signific
denot
p
p
observ
effect
administ
advax
alon
influenza
diseas
recipi
advax
alon
clinic
score
die
rate
salineinject
control
whether
advax
given
im
via
pulmonari
rout
unpublish
data
sinc
highli
immunogen
influenza
viru
strain
use
low
dose
wiv
without
mg
advax
found
optim
avoid
complet
protect
might
induc
antigen
alon
without
adjuv
high
dose
lethal
viral
challeng
found
mice
receiv
nonadjuv
wiv
protect
influenza
infect
evidenc
rapid
weight
loss
clinic
sick
score
within
day
challeng
fig
contrast
mice
receiv
singl
pulmonari
dose
wiv
formul
advax
adjuv
fulli
protect
weight
loss
clinic
diseas
symptom
challeng
fig
cox
mantel
log
rank
test
reveal
differ
surviv
nonadjuv
wiv
advaxadjuv
wiv
group
signific
p
similar
outcom
obtain
upon
repetit
experi
twice
current
studi
demonstr
administr
advaxadjuv
wiv
respiratori
tract
either
liquid
dri
powder
potenti
boost
influenza
induc
system
mucos
cellular
immun
respons
knowledg
first
studi
show
effect
advaxadjuv
dri
powder
influenza
vaccin
formul
full
retent
biolog
activ
wiv
antigen
advax
adjuv
prepar
sfd
though
liquid
dri
powder
influenza
vaccin
formul
use
pulmonari
administr
dri
powder
formul
prefer
due
longterm
stabil
ambient
temperatur
facilit
stockpil
case
influenza
pandem
stockpil
dri
powder
formul
would
readili
avail
easi
administ
mass
vaccin
campaign
advaxadjuv
influenza
formul
pulmonari
rout
found
equal
effect
boost
humor
cellular
immun
howev
pulmonari
rout
found
superior
augment
memori
respons
well
lung
local
factor
moreov
pulmonari
immun
advaxadjuv
wiv
found
equal
effect
im
immun
wiv
term
induct
system
cellular
immun
superior
term
mucos
immun
addit
singl
pulmonari
administr
advaxadjuv
wiv
low
dose
wiv
protect
anim
weight
loss
observ
clinic
symptom
also
led
complet
surviv
contrast
anim
immun
wiv
alon
moreov
advers
effect
weight
loss
sick
seen
anim
receiv
pulmonari
immun
advax
adjuv
henc
inhal
advaxadjuv
influenza
vaccin
either
liquid
dri
powder
formul
may
promis
altern
convent
parenter
influenza
vaccin
studi
limit
includ
fact
impact
vaccin
direct
measur
viru
replic
lung
assess
studi
lung
histolog
perform
detail
aspect
mechan
protect
pulmonari
adjuv
vaccin
safeti
need
studi
futur
howev
expect
enhanc
protect
clinic
diseas
wiv
plu
advax
would
reflect
lower
lung
viru
titer
postchalleng
futur
studi
would
also
interest
investig
increas
tissu
resid
memori
b
cell
respons
elicit
pulmonari
immun
advaxadjuv
wiv
might
contribut
longterm
protect
influenza
short
term
protect
assess
studi
conclus
demonstr
advax
highli
effect
mucos
adjuv
formul
influenza
vaccin
dri
powder
enabl
complet
protect
lethal
influenza
viru
challeng
singl
low
dose
antigen
approach
may
therebi
provid
conveni
needl
free
approach
influenza
vaccin
supplementari
data
articl
found
onlin
http
